Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics

Journal Article · · PLoS ONE
Not Available
Research Organization:
Seattle Genetics, Inc., Bothell, WA (United States)
Sponsoring Organization:
Seattle Genetics Inc; Swiss National Science Foundation; USDOE Office of Science (SC), Basic Energy Sciences (BES)
Grant/Contract Number:
AC02-05CH11231
OSTI ID:
1337464
Alternate ID(s):
OSTI ID: 1903867
Journal Information:
PLoS ONE, Journal Name: PLoS ONE Journal Issue: 8 Vol. 11; ISSN 1932-6203
Publisher:
Public Library of Science (PLoS)Copyright Statement
Country of Publication:
United States
Language:
English

References (33)

Structural Basis of Microtubule Stabilization by Laulimalide and Peloruside A journal January 2014
Large Scale Purification of Brain Tubulin With the Modified Weisenberg Procedure book January 2007
The Dolastatins book January 1997
Dolastatin 10, a powerful cytostatic peptide derived from a marine animal journal June 1990
Natural products which interact with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin a, dolastatins 10 and 15 and halichondrin B journal January 1992
Microtubule Assembly: A Review of Progress, Principles, and Perspectives book January 1984
High-Resolution Microtubule Structures Reveal the Structural Transitions in αβ-Tubulin upon GTP Hydrolysis journal May 2014
Mechanistic Origin of Microtubule Dynamic Instability and Its Modulation by EB Proteins journal August 2015
The Determinants That Govern Microtubule Assembly from the Atomic Structure of GTP-Tubulin journal September 2011
The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization journal April 2014
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery:  Effects of Linker Technology on Efficacy and Toxicity journal January 2006
Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications journal December 2014
Dynamic instability of microtubule growth journal November 1984
Structural insight into the inhibition of tubulin by vinca domain peptide ligands journal September 2008
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain journal March 2004
Structural basis for the regulation of tubulin by vinblastine journal May 2005
Development of potent monoclonal antibody auristatin conjugates for cancer therapy journal June 2003
Microtubules as a target for anticancer drugs journal April 2004
Mitosis is not a key target of microtubule agents in patient tumors journal February 2011
Molecular characterization of human stathmin expressed in Escherichia coli: site-directed mutagenesis of two phosphorylatable serines (Ser-25 and Ser-63) journal June 1994
The binding conformation of Taxol in  -tubulin: A model based on electron crystallographic density journal April 2001
Variations in the colchicine-binding domain provide insight into the structural switch of tubulin journal August 2009
A designed ankyrin repeat protein selected to bind to tubulin caps the microtubule plus end journal July 2012
A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs journal August 2014
Structural basis of tubulin tyrosination by tubulin tyrosine ligase journal January 2013
Role of GTP hydrolysis in microtubule dynamics: information from a slowly hydrolyzable analogue, GMPCPP. journal October 1992
Structural plasticity of tubulin assembly probed by vinca-domain ligands journal July 2012
Structural Insights into the Pharmacophore of Vinca Domain Inhibitors of Microtubules journal December 2015
Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents journal January 2013
Microtubule Polymerization Dynamics journal November 1997
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate journal November 2008
U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma journal September 2012
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity journal August 2003